KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Share-based Compensation (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Share-based Compensation for 16 consecutive years, with $16.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 44.57% to $16.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $51.6 million, a 18.85% increase, with the full-year FY2025 number at $51.6 million, up 18.85% from a year prior.
  • Share-based Compensation was $16.6 million for Q4 2025 at Halozyme Therapeutics, up from $12.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $16.6 million in Q4 2025 to a low of $4.7 million in Q1 2022.
  • A 5-year average of $8.8 million and a median of $9.4 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: dropped 3.68% in 2022, then surged 70.75% in 2023.
  • Halozyme Therapeutics' Share-based Compensation stood at $5.1 million in 2021, then soared by 40.91% to $7.2 million in 2022, then skyrocketed by 33.79% to $9.7 million in 2023, then increased by 18.61% to $11.5 million in 2024, then skyrocketed by 44.57% to $16.6 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Share-based Compensation are $16.6 million (Q4 2025), $12.2 million (Q3 2025), and $12.2 million (Q2 2025).